findmyKOL
Clinical trialNCT04308590CompletedPhase 3Interventional

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

SponsorCorcept TherapeuticsEnrollment137Hypercortisolism
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

45 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria
  • Site 25

    Vienna, State of Vienna, Austria

Bulgaria
  • Site 22

    Sofia, Bulgaria

Germany
  • Site 50

    Munich, Bavaria, Germany

  • Site 46

    Würzburg, Germany

Israel
  • Site 32

    Ramat Gan, Israel

  • Site 23

    Tel Aviv, Israel

Italy
  • Site 40

    Milan, Milano, Italy

  • Site 31

    Rome, Roma, Italy

  • Site 43

    Orbassano, Torino, Italy

  • Site 34

    Milan, Italy

  • Site 28

    Naples, Italy

  • Site 51

    Padova, Italy

  • Site 37

    Rome, Italy

  • Site 52

    Torino, Italy

Poland
  • Site 48

    Gliwice, Poland

  • Site 47

    Krakow, Poland

  • Site 35

    Lublin, Poland

Romania
  • Site 38

    Bucharest, Romania

  • Site 41

    Bucharest, Romania

  • Site 42

    Bucharest, Romania

Spain
  • Site 14

    Málaga, Spain

  • Site 13

    Seville, Spain

  • Site 26

    Valencia, Spain

United States
  • Site 27

    Birmingham, Alabama, United States

  • Site 17

    Stanford, California, United States

  • Site 53

    Torrance, California, United States

  • Site 07

    Atlanta, Georgia, United States

  • Site 16

    Indianapolis, Indiana, United States

  • Site 09

    Metairie, Louisiana, United States

  • Site 36

    Baltimore, Maryland, United States

  • Site 11

    Fall River, Massachusetts, United States

  • Site 33

    Rochester, Minnesota, United States

  • Site 06

    Jackson, Mississippi, United States

  • Site 54

    Reno, Nevada, United States

  • Site 10

    Jamaica, New York, United States

  • Site 44

    New York, New York, United States

  • Site 01

    Wilmington, North Carolina, United States

  • Site 30

    Cleveland, Ohio, United States

  • Site 21

    Columbus, Ohio, United States

  • Site 02

    Summerville, South Carolina, United States

5 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Relacorilant
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Jul 2020
Primary completion
19 Sept 2024
Completion
19 Sept 2024
Last update posted
4 Sept 2025
Registered enrollment
137
Registry id
NCT04308590
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.